Next, we validated the therapeutic effect of eIF4Ai in the chemoresistant MOLM-14 human AML cell line, which harbors a KMT2A/MLLT3 translocation and a FLT3-ITD mutation that constitutively activates mTORC1 signaling in vitro [12]. This evidence concerns the gene MLLT3 and acute myeloid leukemia.